|
Cayman Islands
|
| |
2834
|
| |
98-172573
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(Primary Standard Industrial
Classification Code Number) |
| |
(IRS Employer
Identification Number) |
|
|
Mitchell S. Nussbaum, Esq.
Giovanni Caruso, Esq. Andrei Sirabionian, Esq. Loeb & Loeb LLP 345 Park Avenue New York, New York 10154 Tel: (212) 407-4000 |
| |
Robert Lisicki
1489 W. Warm Springs Rd. #110 Henderson, NV 89014 Tel: (702) 825-9872 |
| |
Stephen P. Alicanti, Esq.
DLA Piper LLP (US) 1251 Avenue of the Americas New York, NY 10020 (212) 335-4500 |
|
| Large accelerated filer | | | ☐ | | |
Accelerated filer
|
| | ☐ | |
|
Non-accelerated filer
|
| | ☒ | | |
Smaller reporting company
|
| | ☒ | |
| | | | | | |
Emerging growth company
|
| | ☒ | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | ii | | | |
| | | | iii | | | |
| | | | iv | | | |
| | | | 1 | | | |
| | | | 13 | | | |
| | | | 15 | | | |
| | | | 65 | | | |
| | | | 75 | | | |
| | | | 87 | | | |
| | | | 95 | | | |
| | | | 100 | | | |
| | | | 100 | | | |
| | | | 100 | | | |
| | | | A-1 | | |
| | |
Three Months
Ended March 31 |
| |
Year
Ended December 31, |
| |
From
January 18, 2022 (date of inception) to December 31, |
| |||||||||||||||
(in millions)
|
| |
2024
|
| |
2023
|
| |
2023
|
| |
2022
|
| ||||||||||||
Consolidated Statements of Operations Data: | | | | | | | | | | | | | | | | | | | | | | | | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | $ | 3,593 | | | | | $ | 4,884 | | | | | $ | 43,999 | | | | | $ | 23,689 | | |
General and administrative
|
| | | | 4,786 | | | | | | 2,835 | | | | | | 18,639 | | | | | | 3,473 | | |
Total operating expenses
|
| | | | 8,379 | | | | | | 7,719 | | | | | | 62,638 | | | | | | 27,162 | | |
Loss from operations
|
| | | | (8,379) | | | | | | (7,719) | | | | | | (62,638) | | | | | | (27,162) | | |
Other (income)/expense, net
|
| | | | (23) | | | | | | 10 | | | | | | (17) | | | | | | 23 | | |
Interest income
|
| | | | (1,215) | | | | | | (1) | | | | | | (2,186) | | | | | | (8) | | |
Dividend income
|
| | | | — | | | | | | — | | | | | | (1,392) | | | | | | — | | |
Change in fair value of private placement warrants
|
| | | | 606 | | | | | | (177) | | | | | | (724) | | | | | | — | | |
Change in fair value of note payable
|
| | | | — | | | | | | 2,244 | | | | | | 2,244 | | | | | | 156 | | |
Loss before income taxes
|
| | | | (7,747) | | | | | | (9,795) | | | | | | (60,563) | | | | | | (27,333) | | |
Income tax expense
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Net loss before redeemable noncontrolling interest
|
| | | | (7,747) | | | | | | (9,795) | | | | | | (60,563) | | | | | | (27,333) | | |
Net loss attributable to redeemable noncontrolling interest
|
| | | | — | | | | | | 203 | | | | | | 203 | | | | | | 1,595 | | |
Net loss
|
| | | | (7,747) | | | | | | (9,592) | | | | | | (60,360) | | | | | | (25,738) | | |
Accretion of redeemable noncontrolling interest to redemption value
|
| | | | — | | | | | | (203) | | | | | | (7,220) | | | | | | (6,652) | | |
Adjustment of redeemable noncontrolling interest from redemption value to carrying value
|
| | | | 7,017 | | | | | | — | | | | | | — | | | | | | — | | |
Deemed contribution from redeemable noncontrolling interest
|
| | | | — | | | | | | — | | | | | | 9,212 | | | | | | — | | |
Deemed dividend to redeemable noncontrolling interest
|
| | | | — | | | | | | — | | | | | | (10,875) | | | | | | — | | |
Net loss attributable to common stockholders
|
| | | | (730) | | | | | | (9,795) | | | | | | (69,243) | | | | | | (32,390) | | |
Net loss per share attributable to Class A Ordinary Shareholders
of Zura, basic and diluted |
| | | $ | (0.02) | | | | | $ | (2.76) | | | | | $ | (2.09) | | | | | $ | (141.97) | | |
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted
|
| | | | 46,914,542 | | | | | | 3,551,906 | | | | | | 33,064,036 | | | | | | 228,148 | | |
| | |
Three
Months Ended March 31 |
| |
Year
Ended December 31, |
| ||||||||||||||||||
Consolidated Statements of Cash Flows Data:
|
| |
2024
|
| |
2023
|
| |
2023
|
| |
2022
|
| ||||||||||||
Net cash used in operating activities
|
| | | $ | (4,982) | | | | | $ | (3,257) | | | | | $ | (15,054) | | | | | $ | (1,202) | | |
Net cash used in investing activities
|
| | | | (5,007) | | | | | | — | | | | | | (8,000) | | | | | | (12,000) | | |
Net cash provided by financing activities
|
| | | | — | | | | | | 45,653 | | | | | | 121,293 | | | | | | 14,769 | | |
| | |
As of
March 31, |
| |
As of
December 31, |
| ||||||||||||
(in millions, except for per share data)
|
| |
2024
|
| |
2023
|
| |
2022
|
| |||||||||
Consolidated Balance Sheets Data: | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | | 89,817 | | | | | | 99,806 | | | | | | 1,567 | | |
Prepaid expenses and other current assets
|
| | | | 657 | | | | | | 1,037 | | | | | | 209 | | |
Total current assets
|
| | | | 90,474 | | | | | | 100,843 | | | | | | 1,776 | | |
Property and equipment, net
|
| | | | 9 | | | | | | — | | | | | | — | | |
Deferred offering costs
|
| | | | — | | | | | | — | | | | | | 3,486 | | |
Total assets
|
| | | | 90,483 | | | | | | 100,843 | | | | | | 5,262 | | |
Accounts payable and accrued expenses
|
| | | | 14,674 | | | | | | 20,302 | | | | | | 4,428 | | |
Note payable
|
| | | | — | | | | | | — | | | | | | 7,756 | | |
Research and development license consideration liability
|
| | | | — | | | | | | — | | | | | | 2,634 | | |
Total current liabilities
|
| | | | 14,674 | | | | | | 20,302 | | | | | | 14,818 | | |
Private placement warrants
|
| | | | 1,596 | | | | | | 990 | | | | | | — | | |
Total liabilities
|
| | | | 16,270 | | | | | | 21,292 | | | | | | 14,818 | | |
Redeemable noncontrolling interest
|
| | | | 11,663 | | | | | | 18,680 | | | | | | 10,000 | | |
Series A-1 convertible preferred shares
|
| | | | — | | | | | | — | | | | | | 12,500 | | |
Total Zura Bio Limited shareholders’ equity (deficit)
|
| | | | 61,009 | | | | | | 59,330 | | | | | | (32,056) | | |
Noncontrolling interest
|
| | | | 1,541 | | | | | | 1,541 | | | | | | — | | |
Total stockholders’ equity (deficit)
|
| | | | 62,550 | | | | | | 60,871 | | | | | | (32,056) | | |
Book value per Class A Ordinary Share
|
| | | $ | 1.30 | | | | | | | | | | | | | | |
Quarter Ended
|
| |
Low Sales
Price of Class A Ordinary Shares |
| |
High Sales
Price of Class A Ordinary Shares |
| |
Low Sales
Price of Public Warrants |
| |
High Sales
Price of Public Warrants |
| ||||||||||||
June 30, 2024
|
| | | $ | 2.42 | | | | | $ | 6.35 | | | | | $ | 0.25 | | | | | $ | 0.88 | | |
March 31, 2024
|
| | | $ | 2.00 | | | | | $ | 4.65 | | | | | $ | 0.17 | | | | | $ | 0.50 | | |
December 31, 2023
|
| | | $ | 3.91 | | | | | $ | 7.22 | | | | | $ | 0.17 | | | | | $ | 0.55 | | |
September 30, 2023
|
| | | $ | 5.56 | | | | | $ | 8.31 | | | | | $ | 0.12 | | | | | $ | 0.64 | | |
June 30, 2023
|
| | | $ | 4.87 | | | | | $ | 15.86 | | | | | $ | 0.18 | | | | | $ | 0.69 | | |
March 31, 2023
|
| | | $ | 6.85 | | | | | $ | 37.55 | | | | | $ | 0.12 | | | | | $ | 0.51 | | |
December 31, 2022
|
| | | $ | 10.04 | | | | | $ | 10.21 | | | | | $ | 0.04 | | | | | $ | 0.16 | | |
September 30, 2022
|
| | | $ | 9.94 | | | | | $ | 10.06 | | | | | $ | 0.12 | | | | | $ | 0.28 | | |
|
Dealer Manager Fees
|
| | | $ | 1,000,000 | | |
|
Legal fees and expenses
|
| | | | 600,000 | | |
|
Accounting fees and expenses
|
| | | | 75,000 | | |
|
Information Agent, printing and mailing, and miscellaneous
|
| | | $ | 75,000 | | |
|
Total
|
| | | $ | 1,750,000 | | |
| | |
Zura Bio Limited
Securities Beneficially Owned Before Exchange of IPO warrants |
| |
Zura Bio Limited
Securities Beneficially Owned Following Exchange of IPO warrants(1) |
| ||||||||||||||||||
Name of Beneficial Owner
|
| |
Number of
Class A Ordinary Shares |
| |
Percentage
of Voting Power |
| |
Number of
Class A Ordinary Shares |
| |
Percentage
of Voting Power |
| ||||||||||||
5% and Greater Shareholders: | | | | | | | | | | | | | | | | | | | | | | | | | |
Entities affiliated with Venrock Healthcare Capital Partners
|
| | | | 6,335,666(2) | | | | | | 9.9% | | | | | | 6,753,166 | | | | | | 9.9% | | |
AI Biotechnology LLC
|
| | | | 6,582,725(3) | | | | | | 9.9% | | | | | | 6,752,725 | | | | | | 9.9% | | |
Entities affiliated with Deep Track Capital, L.P.
|
| | | | 6,216,327(4) | | | | | | 9.3% | | | | | | 6,216,327 | | | | | | 9.2% | | |
Hana Immunotherapeutics LLC
|
| | | | 5,404,274(5) | | | | | | 8.5% | | | | | | 5,404,274 | | | | | | 8.0% | | |
Suvretta Capital Management, LLC
|
| | | | 4,860,939(6) | | | | | | 7.6% | | | | | | 4,860,939 | | | | | | 7.2% | | |
Entities affiliated with Athanor Capital, L.P.
|
| | | | 4,801,633(7) | | | | | | 7.5% | | | | | | 4,801,633 | | | | | | 7.1% | | |
Great Point Partners, LLC
|
| | | | 4,766,529(8) | | | | | | 7.5% | | | | | | 4,766,529 | | | | | | 7.1% | | |
Ewon Comfortech Co., Ltd.
|
| | | | 3,653,466(9) | | | | | | 5.6% | | | | | | 2,496,040 | | | | | | 3.7% | | |
Entities affiliated with RA Capital Management, L.P
|
| | | | 3,217,503(10) | | | | | | 5.0% | | | | | | 3,217,503 | | | | | | 4.8% | | |
Executive Officers and Directors: | | | | | | | | | | | | | | | | | | | | | | | | | |
Robert Lisicki
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Kim Davis
|
| | | | 200,549(11) | | | | | | * | | | | | | 200,549 | | | | | | * | | |
Michael Howell
|
| | | | 98,221(12) | | | | | | * | | | | | | 98,221 | | | | | | * | | |
Verender Badial
|
| | | | 1,003,549(13) | | | | | | 1.6% | | | | | | 709,186 | | | | | | 1.0% | | |
Someit Sidhu
|
| | | | 10,565,321(14) | | | | | | 15.3% | | | | | | 6,932,129 | | | | | | 10.3% | | |
Amit Munshi
|
| | | | 755,514(15) | | | | | | 1.2% | | | | | | 755,514 | | | | | | 1.1% | | |
Sandeep Kulkarni
|
| | | | 348,927(16) | | | | | | * | | | | | | 348,927 | | | | | | * | | |
Arnout Ploos van Amstel
|
| | | | 20,000(17) | | | | | | * | | | | | | 20,000 | | | | | | * | | |
Steve Schoch
|
| | | | 12,433(18) | | | | | | * | | | | | | 12,433 | | | | | | * | | |
Jennifer Jarrett
|
| | | | 12,433(19) | | | | | | * | | | | | | 12,433 | | | | | | * | | |
Neil Graham
|
| | | | 12,433(20) | | | | | | * | | | | | | 12,433 | | | | | | * | | |
Parvinder Thiara
|
| | | | 4,817,683(21) | | | | | | 7.6% | | | | | | 4,817,683 | | | | | | 7.1% | | |
All current named executive officers and directors as a group (12 individuals)
|
| | | | 17,847,063 | | | | | | 25.6% | | | | | | 13,919,508 | | | | | | 20.5% | | |
By: |
|
By: |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Robert Lisicki
Robert Lisicki
|
| |
Chief Executive Officer and Director
(Principal Executive Officer) |
| |
July 25, 2024
|
|
|
*
Verender Badial
|
| |
Chief Financial Officer
(Principal Financial and Accounting Officer) |
| |
July 25, 2024
|
|
|
*
Amit Munshi
|
| |
Chairman of the Board of Directors
|
| |
July 25, 2024
|
|
|
*
Someit Sidhu
|
| |
Director
|
| |
July 25, 2024
|
|
|
*
Sandeep Kulkarni
|
| |
Director
|
| |
July 25, 2024
|
|
|
*
Arnout Ploos van Amstel
|
| |
Director
|
| |
July 25, 2024
|
|
|
*
Steve Schoch
|
| |
Director
|
| |
July 25, 2024
|
|
|
*
Jennifer Jarrett
|
| |
Director
|
| |
July 25, 2024
|
|
|
*
Neil Graham
|
| |
Director
|
| |
July 25, 2024
|
|
|
*
Parvinder Thiara
|
| |
Director
|
| |
July 25, 2024
|
|
|
By First Class Mail:
One State Street, 30th Floor New York, NY 10004 Attn: Corporate Actions Department |
| |
By Overnight or Hand Delivery:
One State Street, 30th Floor New York, NY 10004 Attn: Corporate Actions Department |
|
| Name(s) and Address(es) of Registered Holder(s) of IPO Warrants | | |
Number of IPO Warrants Tendered
Total:
|
|
|
Name:
|
|
|
Address:
|
|
|
Date:
|
|
|
Name:
|
|
|
Capacity:
|
|
|
Address:
|
|
|
Area Code and Telephone Number:
|
|
|
Authorized Signature
|
|
|
Title
|
|
|
Name of Firm
|
|
|
Address, Including Zip Code
|
|
|
Area Code and Telephone Number
|
|
| IPO Warrants | | | Number of IPO Warrants Tendered | |
| | | | Total: | |
| Name of Tendering Institution: | | | | |
| Account Number: | | | | |
|
Signature(s) of IPO Warrant Holder(s)
|
| | ||
|
Name(s) of IPO Warrant Holder(s) (Please Print)
|
| | | |
|
Address
|
| | | |
|
City, State, Zip Code
|
| | | |
|
Telephone Number
|
| | | |
|
Date
|
| | | |
|
Authorized Signature
|
| | | |
|
Name (Please Print)
|
| | | |
|
Title
|
| | | |
|
Name of Firm (must be an Eligible Institution as defined in this Notice of Guaranteed Delivery)
|
| | | |
|
City, State, Zip Code
|
| | | |
|
Date
|
| | | |
|
Authorized Signature Name (Please Print)
|
| | | |
|
Title
|
| | | |
|
Name of Firm
|
| | | |
|
City, State, Zip Code
|
| | | |
|
Date
|
| | | |
| ** | | | | |
| Signature(s): | | | | |
|
Name(s):
|
| |
(Please Print)
|
|
| Taxpayer Identification Number: | | |
|
|
|
Address(es):
|
| |
(Including Zip Code)
|
|
| Area Code/Phone Number: | | |
|
|
| Date: | | | | |